- Lascufloxacin
-
- $2180.00 / 50mg
-
2026-01-05
- CAS:848416-07-9
- Min. Order:
- Purity:
- Supply Ability: 10g
- Lascufloxacin
-
- $2180.00 / 50mg
-
2025-08-22
- CAS:848416-07-9
- Min. Order:
- Purity:
- Supply Ability: 10g
- filgotinib
-
- $1.00 / 1KG
-
2019-07-06
- CAS:848416-07-9
- Min. Order: 1G
- Purity: 98%
- Supply Ability: 100KG
|
| | Lascufloxacin Basic information |
| Product Name: | Lascufloxacin | | Synonyms: | KRP-AM1977X;3-Quinolinecarboxylic acid, 7-[(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoro-1-pyrrolidinyl]-6-fluoro-1-(2-fluoroethyl)-1,4-dihydro-8-methoxy-4-oxo-;KRP-AM1977;Lascufloxacin | | CAS: | 848416-07-9 | | MF: | C21H24F3N3O4 | | MW: | 439.43 | | EINECS: | | | Product Categories: | API | | Mol File: | 848416-07-9.mol |  |
| | Lascufloxacin Chemical Properties |
| Boiling point | 637.0±55.0 °C(Predicted) | | density | 1.44±0.1 g/cm3(Predicted) | | solubility | Chloroform (Slightly), DMSO (Very Slightly) | | form | Solid | | pka | 6.29±0.50(Predicted) | | color | White to Off-White |
| | Lascufloxacin Usage And Synthesis |
| Uses | Lascufloxacin is an intermediate used in the preparation of quinolonecarboxylic acid deriatives as antibacterial agents. | | in vivo | A pharmacodynamic study using a mouse thigh infection model indicates that the ratios of the free area under the curve (fAUC) to MIC in plasma required for bacteriostasis, or 1-log or 2-log CFU killing against S. pneumoniae isolates, are 10, 16, and 28, respectively. Lascufloxacin shows significant bacterial killing in the mouse model when emulated the area under the concentration-time curve (AUC) in plasma in dose of 75 mg per day [q.d.]) [2]. | | IC 50 | Quinolone |
| | Lascufloxacin Preparation Products And Raw materials |
|